Overall, the use of NF-αCTLA4 and NBTXR3 reduced Tregs in both primary and secondary tumors, and both in tandem did so while preserving CD4+ T cell levels and increasing cytotoxic T cell levels in the secondary tumor. Here, CD4 is linked to neoplasm.